Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury.
Undas
Anetta
A
Celińska-Lowenhoff
Magdalena
M
Stepień
Ewa
E
Nizankowski
Rafal
R
Tracz
Wieslawa
W
Szczeklik
Andrzej
A
D000328:Adult; D000368:Aged; D042501:Angiogenic Proteins / Q000097:blood*; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000077214:Becaplermin; D001760:Bleeding Time; D023201:CD40 Ligand / Q000097:blood; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use; D006489:Hemostatic Techniques; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000032:analysis; D020574:Proto-Oncogene Proteins c-sis; D019821:Simvastatin / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D042501:Angiogenic Proteins; D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D023201:CD40 Ligand; D000077214:Becaplermin; D019821:Simvastatin; D011345:Fenofibrate